British Journal of Cancer - Table of Contents alert Volume 108 Issue 2

TABLE OF CONTENTS Volume 108, Issue 2 (245-476) Published online 5 February 2013 In this issue Minireview Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics & Genomics Also new today Advance online publication Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement British Journal of Cancer presents: Web Focus on Lifestyle Lifestyle is now known to contribute significantly to global cancer burdens. We highlight here some recent studies and meta-analyses that identify various factors associated with risk of developing cancer. Read the articles for FREE   Minireview Top Functional genomic screening to enhance oncolytic virotherapy D J Mahoney and D F Stojdl Br J Cancer 2013 108: 245-249; advance online publication, November 20, 2012; 10.1038/bjc.2012.467 Abstract | Full Text Targeted anti-vascular therapies for ovarian cancer: current evidence M Hall, C Gourley, I McNeish, J Ledermann, M Gore, G Jayson, T Perren, G Rustin and S Kaye Br J Cancer 2013 108: 250-258; 10.1038/bjc.2012.541 Abstract | Full Text Clinical Studies Top Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone G R Lauretti, C C Rizzo, A L Mattos and S W Rodrigues Br J Cancer 2013 108: 259-264; advance online publication, January 15, 2013; 10.1038/bjc.2012.593 Abstract | Full Text A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer A Atmaca, S-E Al-Batran, D Werner, C Pauligk, T Güner, A Koepke, H Bernhard, T Wenzel, A-G Banat, P Brueck, K Caca, N Prasnikar, F Kullmann, H Günther Derigs, M Koenigsmann, G Dingeldein, T Neuhaus and E Jäger Br J Cancer 2013 108: 265-270; advance online publication, January 17, 2013; 10.1038/bjc.2012.555 Abstract | Full Text Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort G Fisher, Z H Yang, S Kudahetti, H Møller, P Scardino, J Cuzick and D M Berney on behalf of the Transatlantic Prostate Group Br J Cancer 2013 108: 271-277; advance online publication, January 17, 2013; 10.1038/bjc.2012.598 Abstract | Full Text Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer R Bertorelle, M Briarava, E Rampazzo, L Biasini, M Agostini, I Maretto, S Lonardi, M L Friso, C Mescoli, V Zagonel, D Nitti, A De Rossi and S Pucciarelli Br J Cancer 2013 108: 278-284; advance online publication, January 15, 2013; 10.1038/bjc.2012.602 Abstract | Full Text Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas Y Delpech, C Coutant, L Hsu, E Barranger, T Iwamoto, C H Barcenas, G N Hortobagyi, R Rouzier, F J Esteva and L Pusztai Br J Cancer 2013 108: 285-291; advance online publication, January 8, 2013; 10.1038/bjc.2012.557 Abstract | Full Text Differences in cancer awareness and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): do they contribute to differences in cancer survival? L J L Forbes, A E Simon, F Warburton, D Boniface, K E Brain, A Dessaix, C Donnelly, K Haynes, L Hvidberg, M Lagerlund, G Lockwood, C Tishelman, P Vedsted, M N Vigmostad, A J Ramirez and J Wardle the International Cancer Benchmarking Partnership Module 2 Working Group Br J Cancer 2013 108: 292-300; advance online publication, January 31, 2013; 10.1038/bjc.2012.542 Abstract | Full Text Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours G Yadegarfar, L Friend, L Jones, L M Plum, J Ardill, B Taal, G Larsson, K Jeziorski, D Kwekkeboom and J K Ramage on behalf of the EORTC Quality of Life Group Br J Cancer 2013 108: 301-310; advance online publication, January 15, 2013; 10.1038/bjc.2012.560 Abstract | Full Text Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis G Procopio, J Bellmunt, J Dutcher, S Bracarda, J Knox, A Brueckner, I Molnar, B Escudier and T E Hutson Br J Cancer 2013 108: 311-318; advance online publication, January 15, 2013; 10.1038/bjc.2012.543 Abstract | Full Text Translational Therapeutics Top Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts X Wang, L Zhang, A O'Neill, B Bahamon, D C Alsop, J W Mier, S N Goldberg, S Signoretti, M B Atkins, C G Wood and R S Bhatt Br J Cancer 2013 108: 319-326; advance online publication, January 15, 2013; 10.1038/bjc.2012.591 Abstract | Full Text Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo W C Duivenvoorden, L K Beatty, S Lhotak, B Hill, I Mak, G Paulin, D Gallino, S Popovic, R C Austin and J H Pinthus Br J Cancer 2013 108: 327-333; advance online publication, January 15, 2013; 10.1038/bjc.2012.574 Abstract | Full Text Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts C Eicher, A Dewerth, J Thomale, V Ellerkamp, S Hildenbrand, S W Warmann, J Fuchs and S Armeanu-Ebinger Br J Cancer 2013 108: 334-341; advance online publication, December 20, 2012; 10.1038/bjc.2012.539 Abstract | Full Text A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth M Kaliszczak, S Trousil, O Åberg, M Perumal, Q-D Nguyen and E O Aboagye Br J Cancer 2013 108: 342-350; advance online publication, January 15, 2013; 10.1038/bjc.2012.576 Abstract | Full Text Molecular Diagnostics Top Tissue biomarkers of breast cancer and their association with conventional pathologic features L Chung, S Shibli, K Moore, E E Elder, F M Boyle, D J Marsh and R C Baxter Br J Cancer 2013 108: 351-360; advance online publication, January 8, 2013; 10.1038/bjc.2012.552 Abstract | Full Text Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer T Kawaguchi, S Komatsu, D Ichikawa, R Morimura, M Tsujiura, H Konishi, H Takeshita, H Nagata, T Arita, S Hirajima, A Shiozaki, H Ikoma, K Okamoto, T Ochiai, H Taniguchi and E Otsuji Br J Cancer 2013 108: 361-369; advance online publication, January 17, 2013; 10.1038/bjc.2012.546 Abstract | Full Text The epigenetic landscape of oral squamous cell carcinoma P V Jithesh, J M Risk, A G Schache, J Dhanda, B Lane, T Liloglou and R J Shaw Br J Cancer 2013 108: 370-379; advance online publication, January 3, 2013; 10.1038/bjc.2012.568 Abstract | Full Text Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type Q Cai, X Luo, Y Liang, H Rao, X Fang, W Jiang, T Lin, T Lin and H Huang Br J Cancer 2013 108: 380-386; advance online publication, January 8, 2013; 10.1038/bjc.2012.566 Abstract | Full Text Erythrocyte sedimentation rate and anaemia are independent predictors of survival in patients with clear cell renal cell carcinoma Y Choi, B Park, K Kim, B C Jeong, S I Seo, S S Jeon, H Y Choi, J E Lee and H M Lee Br J Cancer 2013 108: 387-394; advance online publication, January 8, 2013; 10.1038/bjc.2012.565 Abstract | Full Text REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer A Sekikawa, H Fukui, X Zhang, T Maruo, T Tsumura, Y Okabe, T Wakasa, Y Osaki, T Chiba, T Tomita, T Oshima, J Watari and H Miwa Br J Cancer 2013 108: 395-401; advance online publication, January 15, 2013; 10.1038/bjc.2012.572 Abstract | Full Text Lacking hypoxia-mediated downregulation of E-cadherin in cancers of the uterine cervix A Mayer, M Höckel, N Schlischewsky, H Schmidberger, L-C Horn and P Vaupel Br J Cancer 2013 108: 402-408; advance online publication, January 15, 2013; 10.1038/bjc.2012.570 Abstract | Full Text Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells K M Dixon, G Y L Lui, Z Kovacevic, D Zhang, M Yao, Z Chen, Q Dong, S J Assinder and D R Richardson Br J Cancer 2013 108: 409-419; advance online publication, January 3, 2013; 10.1038/bjc.2012.582 Abstract | Full Text Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer K D Sørensen, M O Abildgaard, C Haldrup, B P Ulhøi, H Kristensen, S Strand, C Parker, S Høyer, M Borre and T F Ørntoft Br J Cancer 2013 108: 420-428; advance online publication, January 15, 2013; 10.1038/bjc.2012.549 Abstract | Full Text Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations D J Pinato, R Ramachandran, S T K Toussi, M Vergine, N Ngo, R Sharma, T Lloyd, K Meeran, F Palazzo, N Martin, B Khoo, R Dina and T M Tan Br J Cancer 2013 108: 429-437; advance online publication, December 20, 2012; 10.1038/bjc.2012.538 Abstract | Full Text Genetics & Genomics Top An intronic polymorphic deletion in the PTEN gene: implications for molecular diagnostic testing S Sandell, R J L Schuit and D J Bunyan Br J Cancer 2013 108: 438-441; advance online publication, January 8, 2013; 10.1038/bjc.2012.562 Abstract | Full Text Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells S Carbajo-Pescador, C Steinmetz, A Kashyap, S Lorenz, J L Mauriz, M Heise, P R Galle, J González-Gallego and S Strand Br J Cancer 2013 108: 442-449; advance online publication, December 20, 2012; 10.1038/bjc.2012.563 Abstract | Full Text Lack of correlation between predicted and actual off-target effects of short-interfering RNAs targeting the human papillomavirus type 16 E7 oncogene J E Hanning, H K Saini, M J Murray, S van Dongen, M P A Davis, E M Barker, D M Ward, C G Scarpini, A J Enright, M R Pett and N Coleman Br J Cancer 2013 108: 450-460; advance online publication, January 8, 2013; 10.1038/bjc.2012.564 Abstract | Full Text An inherited NBN mutation is associated with poor prognosis prostate cancer C Cybulski, D Wokołorczyk, W Kluźniak, A Jakubowska, B Górski, J Gronwald, T Huzarski, A Kashyap, T Byrski, T Dębniak, A Gołąb, B Gliniewicz, A Sikorski, J Świtała, T Borkowski, A Borkowski, A Antczak, Ł Wojnar, J Przybyła, M Sosnowski, B Małkiewicz, R Zdrojowy, P Sikorska-Radek, J Matych, J Wilkosz, W Różański, J Kiś, K Bar, P Bryniarski, A Paradysz, K Jersak, J Niemirowicz, P Słupski, P Jarzemski, M Skrzypczyk, J Dobruch, P Domagała, S A Narod and J Lubiński the Polish Hereditary Prostate Cancer Consortium Br J Cancer 2013 108: 461-468; advance online publication, November 13, 2012; 10.1038/bjc.2012.486 Abstract | Full Text EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 S Boeck, A Jung, R P Laubender, J Neumann, R Egg, C Goritschan, U Vehling-Kaiser, C Winkelmann, L Fischer von Weikersthal, M R Clemens, T C Gauler, A Märten, S Klein, G Kojouharoff, M Barner, M Geissler, T F Greten, U Mansmann, T Kirchner and V Heinemann Br J Cancer 2013 108: 469-476; advance online publication, November 20, 2012; 10.1038/bjc.2012.495 Abstract | Full Text Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.